Ce Shi, PhD1,2*, Lina Han, PhD1*, Qi Zhang3*, Kathryn G. Roberts4, Eugene Park5*, Yoko Tabe, MD, PhD6, Rodrigo Omar Jacamo, PhD3*, Hong Mu, MD, PhD7*, Shuo-Chieh Wu8*, Jin Zhou9*, Helen Ma1*, Zhihong Zeng, MD10, Nitin Jain, MD1, Elias J Jabbour, MD1, Markus Muschen, MD PhD11, Sarah K Tasian, MD12, Charles G. Mullighan, MBBS, MSc, MD13, David M. Weinstock14, David Fruman, PhD15* and Marina Konopleva, MD, PhD10
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, First Affiliated Hospital, Harbin Medical University, Harbin, China
3Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Pathology, St. Jude Children's Research Hospital, Memphis, TN
5Department of Haematology, University of Cambridge, Cambridge, United Kingdom
6Juntendo University School of Medicine, Toyko, Japan
7Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
8Dana-Farber Cancer Institute, Boston, MD
9Department of Medicine, Hematology, The First Hospital Affiliated Harbin Medical University, Harbin, China
10Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
11Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
12Pediatric Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA
13Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
14Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
15University of California, Irvine, Irvine, CA